Tormentic Acid Ameliorates Hepatic Fibrosis

glycerophospholipid metabolism pathway liver fibrosis metabolomics tormentic acid transcriptomics

Journal

Frontiers in pharmacology
ISSN: 1663-9812
Titre abrégé: Front Pharmacol
Pays: Switzerland
ID NLM: 101548923

Informations de publication

Date de publication:
2022
Historique:
received: 26 10 2021
accepted: 31 01 2022
entrez: 1 4 2022
pubmed: 2 4 2022
medline: 2 4 2022
Statut: epublish

Résumé

This study aimed to investigate the effects and underlying mechanisms of tormentic acid (TA) on carbon tetrachloride (CCl

Identifiants

pubmed: 35359829
doi: 10.3389/fphar.2022.801982
pii: 801982
pmc: PMC8963336
doi:

Types de publication

Journal Article

Langues

eng

Pagination

801982

Informations de copyright

Copyright © 2022 Lin, Wei, Li, Xiong, Fang, Li, Huang, Huang and Wei.

Déclaration de conflit d'intérêts

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Références

J Biol Chem. 2021 Dec;297(6):101331
pubmed: 34688661
Toxicol Lett. 2020 Oct 15;333:290-302
pubmed: 32835833
Am J Physiol Gastrointest Liver Physiol. 2019 Apr 1;316(4):G539-G550
pubmed: 30735452
Nat Commun. 2018 Aug 22;9(1):3369
pubmed: 30135572
Mol Aspects Med. 2019 Feb;65:37-55
pubmed: 30213667
Liver Int. 2015 Apr;35(4):1222-33
pubmed: 25040634
J Ethnopharmacol. 2020 May 23;254:112714
pubmed: 32105750
J Pharm Biomed Anal. 2021 Jun 5;200:114073
pubmed: 33873073
Clin Biochem. 2005 Dec;38(12):1138-40
pubmed: 16242682
Nat Rev Gastroenterol Hepatol. 2011 Feb;8(2):108-18
pubmed: 21293511
Bioinformatics. 2014 Aug 1;30(15):2114-20
pubmed: 24695404
Source Code Biol Med. 2014 May 03;9:8
pubmed: 24955109
Biomed Pharmacother. 2019 Aug;116:108923
pubmed: 31154269
Sci Rep. 2017 Sep 12;7(1):11433
pubmed: 28900168
Oncotarget. 2015 Mar 30;6(9):7325-38
pubmed: 25356754
Chem Biol Interact. 2019 Aug 25;309:108675
pubmed: 31150632
Biomed Pharmacother. 2019 Jul;115:108901
pubmed: 31079002
J Ethnopharmacol. 2020 Nov 15;262:113275
pubmed: 32810620

Auteurs

Xing Lin (X)

Guangxi Medical University Life Sciences Institute, Nanning, China.

Yuanyuan Wei (Y)

Pharmaceutical College, Guangxi Medical University, Nanning, China.

Yan Li (Y)

Guangxi Medical University Life Sciences Institute, Nanning, China.

Yuhua Xiong (Y)

Guangxi Medical University Life Sciences Institute, Nanning, China.

Bin Fang (B)

Guangxi Medical University Life Sciences Institute, Nanning, China.

Cuiyu Li (C)

Guangxi Medical University Life Sciences Institute, Nanning, China.

Quanfang Huang (Q)

The Pharmaceutical Department, Guangxi University of Chinese Medicine First Affiliated Hospital, Nanning, China.

Renbin Huang (R)

Pharmaceutical College, Guangxi Medical University, Nanning, China.

Jinbin Wei (J)

Pharmaceutical College, Guangxi Medical University, Nanning, China.

Classifications MeSH